Literature DB >> 16734242

[REMEEX: A possible treatment option in selected cases of sphincter incompetence].

Jean-Louis Campos-fernandes1, Marc-Olivier Timsit, Philippe Paparel, Marian Devonec, Béatrice Leriche, Albert Leriche, Alain Ruffion.   

Abstract

OBJECTIVE: To evaluate the functional results and morbidity of adjustable tension suburethral tape (REMEEX) in the treatment of urinary incontinence due to severe sphincter incompetence (MUCP < 40 cm H2O) in patients presenting a contraindication to artificial sphincter operated between December 2001 and May 2004. Twelve patients (66.7%) had already undergone incontinence surgery. Ten patients (55.5%) had mixed urinary incontinence. The efficacy of the tape was considered to be good when incontinence resolved completely, partial when incontinence was decreased by > 50% and/or PVR > 100 ml. All other cases were considered to be failures. In April 2005, after a mean follow-up of 26.3 months, retrospective evaluation of the functional results was performed by means of a pad-test and a questionnaire comprising an MHU (urinary disability) score and a Ditrovie score. Complications after each intercurrent event were recorded.
RESULTS: The initial efficacy of the tape was considered to be good in 13 patients (72.2%) and partial in 4 patients (22.2%) with only one initial failure. Eight patients (44.4%) required secondary adjustment after a mean interval of 5.2 months, with a failure rate of 62.5%. In April 2005, 10 patients (55.5%) had a good result, 2 patients (11.1%) required self-catheterization (partial efficacy) and 6 patients (33.4%) were considered to be failures. In terms of morbidity, we observed 2 bladder injuries (11.1%), 6 superinfections of the device (33.3%), 2 (11.1%) of which required removal of the material. Fifteen patients (83.3%) answered the questionnaire: 6 patients (40%) had an MHU score greater than 3. The mean Ditrovie score was 2.1. 9 patients (60%) had a score less than 2 and 4 patients (26.6%) had a score greater than 3.
CONCLUSION: The results of this series, in patients in whom artificial sphincter was contraindicated, are satisfactory at the price of acceptable morbidity. Before defining the place of this device in the range of treatment options for sphincter incompetence, our results must be confirmed by a longer series.

Entities:  

Mesh:

Year:  2006        PMID: 16734242

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  7 in total

Review 1.  [New techniques for surgical treatment of postoperative male stress incontinence].

Authors:  S Bross; S T Kwon; S Peter; P Honeck
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639

Review 2.  [Diagnosis and surgical treatment of postprostatectomy stress incontinence: recommendation of the working group Urologische Funktionsdiagnostik und Urologie der Frau].

Authors:  R M Bauer; C Hampel; A Haferkamp; K Höfner; W Hübner
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639

3.  [Urogynecology II: urinary incontinence in men and women: surgical treatment of urinary incontinence and prolapse].

Authors:  M F Hamann; C M Naumann; S Knüpfer; K P Jünemann; R Bauer
Journal:  Urologe A       Date:  2014-11       Impact factor: 0.639

4.  [Urinary incontinence in men].

Authors:  R M Bauer; M Oelke; W Hübner; M Grabbert; R Kirschner-Hermanns; R Anding
Journal:  Urologe A       Date:  2015-06       Impact factor: 0.639

5.  [Modern operative treatment possibilities in male stress urinary incontinence].

Authors:  R M Bauer; A Kretschmer; W Hübner
Journal:  Urologe A       Date:  2014-03       Impact factor: 0.639

6.  Slings in iatrogenic male incontinence: Current status.

Authors:  Fabrizio Gallo; M Schenone; C Giberti
Journal:  Indian J Urol       Date:  2010-04

7.  Assessing the Readjustable Sling Procedure (Remeex System) for Female Stress Urinary Incontinence With Detrusor Underactivity.

Authors:  Kwang Jin Ko; Yoon Seok Suh; Hyun Hwan Sung; Gyu Ha Ryu; Munjae Lee; Kyu-Sung Lee
Journal:  Int Neurourol J       Date:  2017-06-21       Impact factor: 2.835

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.